Transfer of complex regional pain syndrome to mice via human autoantibodies is mediated by interleukin-1-induced mechanisms. by Helyes, Zsuzsanna et al.
Transfer of Complex Regional Pain Syndrome to mice via human autoantibodies is mediated by interleukin-1-induced mechanisms

Zsuzsanna Helyes1,4,#§, Valéria Tékus1#, Nikolett Szentes1#, Krisztina Pohóczky1,9, Bálint Botz1, Tamás Kiss1, Ágnes Kemény1, 
Zsuzsanna Környei2, Krisztina Tóth2, Nikolett Lénárt2, Hajnalka Ábrahám3, Emmanuel Pinteaux 5, Sheila Francis6, Serena Sensi7, Ádám Dénes2,5§ and Andreas Goebel7,8§

1Department of Pharmacology and Pharmacotherapy, Medical School; János Szentágothai Research Centre & Centre for Neuroscience, University of Pécs, Pécs, Hungary
2Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary
3Department of Biology and Electron Microscopy, Medical School, University of Pécs, Pécs, Hungary
4PharmInVivo Ltd., Pécs, Hungary
5Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine, and Health. University of Manchester, Manchester, UK.
6Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
7Department of Translational Medicine, University of Liverpool, Liverpool, UK
8The Walton Centre NHS Foundation Trust, Liverpool, UK
9Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Pécs, Hungary


#Zs. Helyes, V. Tékus and N. Szentes made equal contributions to the present work.

§A. Goebel, Zs. Helyes and A. Denes are indicated as equal corresponding authors in this paper.
Clinical work, IgG preparation: A. Goebel, Pain Research Institute, Department of Translational
Medicine, University of Liverpool, Liverpool L7 7AL, UK. Tel.: +44 151 529 5820; fax:
+44 151 529 5821; e-mail: andreasgoebel@rocketmail.com (​mailto:andreasgoebel@rocketmail.com​), andreas.goebel@liv.ac.uk (​mailto:andreas.goebel@liv.ac.uk​)
Animal experiments: Zs Helyes, University of Pécs Medical School, Department of Pharmacology and Pharmacotherapy & Szentagothai Research Centre. Tel: +36 72 5202802; fax: +36 72 536218; e-mail: zsuzsanna.helyes@aok.pte.hu (​mailto:zsuzsanna.helyes@aok.pte.hu​)
IL-1 gene-deleted mice and neuroinflammation: A. Denes; Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary. Tel:+36209549149; e-mail: denesa@koki.hu (​mailto:denesa@koki.hu​)


Abstract
Neuro-immune interactions may contribute to severe pain, and regional inflammatory and autonomic signs in Complex Regional Pain Syndrome (CRPS), a post-traumatic pain disorder. Here we investigated peripheral and central immune mechanisms in a translational passive transfer-trauma mouse model of CRPS. Small plantar skin-muscle incision was performed in female C57Bl/6 mice treated daily with purified serum-IgG from patients with longstanding CRPS, or healthy volunteers, followed by assessment of paw edema, hyperalgesia, inflammation, and central glial activation. CRPS IgG significantly increased and prolonged swelling and induced stable hyperalgesia of the incised paw compared to IgG from healthy controls. Following a short-lasting paw inflammatory response in all groups, CRPS IgG-injected mice displayed sustained, profound microglia and astrocyte activation in the dorsal horn of the spinal cord and in pain-related brain regions, indicating central sensitization. Genetic deletion of interleukin-1 (IL-1) using IL-1αβ knockout (KO) mice, and perioperative IL-1 receptor type 1 (IL-1R1) blockade with the drug anakinra, but not treatment with the glucocorticoid prednisolone, prevented these changes. Anakinra treatment also reversed the established sensitization phenotype when initiated 8 days after incision. Furthermore, with the generation of a novel IL-1β floxed(fl/fl) mouse line, we demonstrated that CRPS IgG-induced changes are in part mediated by microglia-derived IL-1β, suggesting that both peripheral and central inflammatory mechanisms contribute to the transferred disease phenotype. These results indicate that persistent CRPS is often contributed to by autoantibodies and highlight a potential novel therapeutic use for clinically licensed antagonists, such as anakinra, to prevent or treat CRPS via blocking IL-1 actions.

Significance Statement: Complex Regional Pain Syndrome (CRPS) is a poorly understood painful condition which typically arises after distal limb trauma; 20% of patients may develop lifelong severe incessant pain with few therapeutic options. In this study we show that IgG autoantibodies from patients with severe, persistent CRPS, upon transfer to hindpaw-injured mice elicit important features of the clinical condition, and profound glial activation in pain-related brain regions. Blockade of the proinflammatory cytokine, interleukin-1 (IL-1) both prevents and reverses these changes. Our findings suggest that antibody-mediated autoimmunity contributes to the development of severe CRPS after injury and that blockade of IL-1 actions may be an attractive therapeutic prospect. Investigation of autoantibody contribution to other unexplained chronic pain syndromes appears warranted.



\body

INTRODUCTION

Complex Regional Pain Syndrome (CRPS), with a prevalence of about 1:2000, is a chronic pain condition experienced by humans. CRPS is usually triggered by trauma to the distal regions of a limb, and is further associated with limb-restricted edema, sensory, vasomotor, sudomotor, motor, and trophic abnormalities, and profound sensory central nervous system (CNS) reorganisation (1). In CRPS, typically no or only minimal tissue destruction occurs (2), and although morphological change such as disuse atrophy can sometimes be observed, this is not thought to explain the experienced intense pain  ADDIN EN.CITE (3). The underlying pathophysiological mechanisms are poorly understood. Systemic inflammatory markers remain normal in CRPS patients, but regional inflammatory mediators and autoimmunity are suggested to contribute to the manifestation of the symptoms (4). Furthermore, neuro-plasticity mechanisms within the spinal cord and the brain are believed to sustain persistent pain  ADDIN EN.CITE (5).
While most patients with CRPS show an improvement within months, either with or without treatment (6), 20% of patients develop persistent pain, often lasting for years or even through their lifetime (7). This type of persistent pain is intrusive and results in amongst the lowest quality of life scores in medical conditions (8). Among the few drug trials performed to date (9) neither conventional drugs used to relieve pain, (i.e. non-steroidal anti-inflammatory drugs, opioids, anti-depressants, or anti-convulsants), nor steroids have shown significant efficacy in persistent CRPS. Implantation of a spinal cord stimulator, which delivers electrical impulses to the dorsal column can over-ride CRPS pain in about 50% of patients, but the duration of the optimum effect is limited (9). Since many patients cannot be successfully treated, the treatment of CRPS remains an important unresolved problem and is still an unmet medical need (10). Thus, to better understand the peripheral and central pathophysiological mechanisms underlying CRPS, reliable and validated animal models are desperately needed (2)
We have recently shown that passive transfer of serum-IgG from CRPS patients to hindpaw-injured rodents elicits key features (unilateral hyperalgesia and edema) of the clinical condition  ADDIN EN.CITE (11). This suggests a ‘two-hit’ process, where circulating IgG autoantibodies (i.e. the first ‘hit’)  are rendered pathogenic in the context of paw injury (the second ‘hit’) related regional or central modifications (2). Although these behavioural results indicated that serum IgG autoantibodies contribute to the disease pathophysiology, and thus provided the first evidence for the construct-validity of the transfer model, the observed abnormalities were modest and short-lasting, and the mechanisms mediating them have remained unknown.
Using samples available from patients who consented to repeat donation of larger blood volumes, or who had received plasma exchange treatment  ADDIN EN.CITE (12), we have now developed an enhanced passive IgG transfer-trauma model, and have examined its translational validity. We investigated: i) whether and how the transferred behavioural signs in rodents are augmented and sustained with daily human immunoglobulin G injections,, and whether there are differences between preparations from different patients, ii) the degree of regional post-traumatic immune activation in the paw, given that mild, transient immune activation in the affected skin is sometimes detected in patients (13), and its correlation to behavioural parameters, iii) the degree and mechanisms of post-traumatic glial activation in the spinal dorsal horn since strong CNS re-organisation is recognized in the clinical cases  ADDIN EN.CITE (5), and finally iv) whether targeting specific inflammatory pathways at the time of, or after trauma can prevent or reverse transferred CRPS (‘tCRPS’) to provide a translatable therapeutic approach. 


RESULTS

Daily administration of serum IgG from CRPS patients induces profound and persistent post-incisional mechanical hyperalgesia
The pre-operation mechanonociceptive threshold values of the affected limbs were 8.65  0.08, 8.69  0.09 and 8.60  0.07 in the saline, healthy IgG- and CRPS IgG-treated mice, respectively (not significantly different, Fig. 1A). Plantar skin and muscle incision induced a 45-50 % relative decrease of the mechanonociceptive threshold in all groups one day after the surgery. Upon daily injections, paw sensitivity quickly recovered to mild hyperalgesia in both saline and healthy IgG-injected animals, with mild, non-significantly enhanced values remaining in the healthy IgG group versus the saline group throughout the experimental period. Injection of IgG from CRPS patients caused significantly augmented hyperalgesia compared to IgG from healthy volunteers, which appeared to be further enhanced towards the end of the experimental period. This effect was evident in the IgG preparations from each individually tested patient (n=7), as well as a preparation pooled from 7 separate patients (SI appendix Fig. S1). The observed 15-32% absolute threshold reduction was two-fold compared to that seen in our previously published experimental model (injections on day -1, 0, 5, 6)  ADDIN EN.CITE (11). Contralateral paws retained normal sensitivity in all groups (SI appendix Fig.S2). 

In all groups, injured paws developed about 30% relative paw swelling (defined as edema) on day 1, but there were no changes in contralateral paws (SI appendix Fig. S3). Edema resolved in healthy IgG and saline groups, but CRPS IgG injection significantly slowed edema resolution (Fig. 1B). While the pattern of transferred hyperalgesia was uniform, there was important variability in the degree and pattern of transferred swelling between different patient preparations, with no correlation between these two parameters (SI appendix Figs. S2-3). Post-surgery minimal weight loss was observed compared with baseline for a few days, and the weights of the animal then fully recovered, without significant differences between groups (SI appendix Fig. S4). We observed no spontaneous nocifensive behaviours, such as paw biting, lifting or licking.

CRPS IgG does not alter vascular plasma leakage, but increases neutrophil MPO activity early after paw incision 
Indocyanin green (ICG) - derived fluorescence detecting vascular leakage showed a non-significant trend to increase in the injured paws in all groups two days after paw incision;  CRPS-IgG did not specifically affect plasma-extravasation (saline injured: 1.52 x 109  1.11 x 108; healthy IgG injured: 1.42 x 109  1.54 x 108; CRPS IgG injured: 1.70 x 109  2.2 x 108; fluorescence intensity: (photons/second/cm2/steradian)/W/cm2).
 As expected, in vivo imaging of L-012 derived bioluminescence, used as a sensitive marker of inflammatory cell activity (most prominently neutrophil-derived myeloperoxidase (MPO)) showed increased signal in response to limb trauma alone (Fig.2). We found a significant increase in neutrophil MPO-activity in the CRPS IgG-treated animals on the affected side two days after the incision, when compared to the control groups. Differences in MPO-activity in CRPS IgG versus healthy IgG groups had disappeared by day 6, although significant increases in the injured paw were still present compared to the intact side on day 13. Importantly, while strong variability was observed between different IgG preparations in influencing MPO-activity (SI appendix Fig. S5 and Table S2), bioluminescence measured on day 2 or 6 did not correlate with either maximal paw swelling or hyperalgesia on day 6. This suggests that altered MPO activity in the injured paw of tCRPS mice is an unrelated IgG effect that is unlikely to explain the marked impact of CRPS IgG on paw hypersensitivity.

CRPS IgG does not promote inflammation or neuropathy in the paw
We further examined whether the tCRPS behavioural signs were related to locally augmented inflammatory responses or to neuropathic changes. In successive experiments, animals were sacrificed between experimental days 1-13 and paw tissues harvested to assess various inflammatory changes (animal numbers and preparations supplementary Table S3). 
Substance P (SP) levels increased in the injured paw, with higher levels in the CRPS IgG group on day 6 (Fig. 3A), whereas calcitonin gene related peptide (CGRP) levels were not significantly altered (Fig. 3B), consistent with earlier findings  ADDIN EN.CITE (11). Increased levels of inflammatory mediators were seen in the injured paws, with gradual decrease over time (shown in Fig. 3C-F for interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), interleukin-1 (IL-1β), and in the SI appendix S6 for additional mediators). We detected no differences in the levels of inflammatory mediators between the CRPS and healthy IgG groups (Figure 3C-F, SI appendix S6) at any time point, except for a mild CRPS IgG-induced MCP-1 increase at day 13 (Fig. 3E). Notably, at the time of maximum hyperalgesia, 13 days post-injury, most mediators were undetectable. There were no significant changes in plasma concentrations of any cytokines after correction for multiple testing (SI appendix Fig. S7).
Histological examination revealed moderate infiltration of inflammatory cells into areas immediately adjacent to the incision early after surgery, with no obvious difference between groups; there was no evidence of infiltration by inflammatory cells on day 13 in any experimental group. Since some patients with persistent CRPS exhibit mild small fibre neuropathy  ADDIN EN.CITE (14), we also examined mouse paw biopsies from CRPS IgG injected animals for any evidence of structural changes to small skin nerves with both light- and electron microscopy. The morphology of the axons in the right (injured) and left (intact) paws, as well as the ultrastructure of non-myelinated and thin-myelinated axons in the dermis appeared very similar on aspect, and there were no significant differences between sides upon quantification of axon numbers and diameters (Table S4).

CRPS-IgG facilitates sustained microglia activation in the CNS 
We next investigated whether altered activity of microglia or astrocytes in pain-related circuits (15) would reflect the marked effects of CRPS IgG on pain sensitivity responses. In CNS areas receiving input from the injured paw, CRPS IgG-induced remarkable increases in both astrocyte and microglia cell activity when compared to both saline and healthy IgG groups. In the dorsal horn, this response was sometimes much stronger than the increases representing the incision trauma (Fig. 4). Astrocyte reactivity in the CRPS IgG animals was augmented in all CNS areas at early time points (day 3 and day 6), whereas microglia staining was enhanced throughout the experimental period including day 13 (Fig. 4 and Fig. S9) indicating that increased mechanical hypersensitivity in this model is associated with transient astrocyte-, and persistent microglial activation in the CNS.

Early IL-1 receptor blockade with anakinra prevents the development of tCRPS, while delayed anakinra treatment reverses established tCRPS and reduces glial activation.  
Since both microglia and astrocytes are important sources of proinflammatory cytokines that are known to contribute to pain hypersensitivity responses  ADDIN EN.CITE (16, 17) and interleukin-1 is a key mediator that influences neuronal activity  ADDIN EN.CITE (18, 19), we investigated the effects of glucocorticoid (prednisolone) treatment or IL-1 receptor antagonist (anakinra) treatment on CRPS IgG-induced behavioural signs and inflammatory changes. Prednisolone (4 mg/kg), or anakinra (10 mg/kg) were daily administered intraperitoneally, starting 5h prior to surgery (day 0) and extending throughout the experimental period. One day after surgery, mechanical hyperalgesia developed equally in all groups (Fig. 5A-B). Glucocorticoid treatment transiently reduced CRPS IgG-induced mechanical hyperalgesia (between days 2 and 3), but this effect was lost by day 7. In contrast, anakinra prevented all CRPS IgG-induced effects throughout the experimental period (Fig. 5B). Anakinra, but not prednisolone treatment almost completely reversed glia cell activation in the ipsilateral dorsal horn, on day 6 (Fig.5 D-E). Notably, anakinra treatment also significantly reduced paw MCP1 levels on day 3, however there were no other differential effects on levels of peripheral mediators between these two treatments (SI appendix Fig. S10). Furthermore, delayed administration of anakinra starting from day 8 onwards reversed the established tCRPS phenotype (Fig. 5C), and completely reversed the associated increased dorsal horn microglia activation on day 13 (Fig. 5F).


Selective deletion of microglial IL-1β ameliorates, while ubiquitous deletion of IL-1αβ completely prevents tCRPS.  
Given that CRPS IgG caused significant dorsal horn glia cell activation without influencing paw IL-1 levels, and that blockage of IL-1 prevented the tCRPS phenotype, we then investigated whether tCRPS was associated with enhanced glial IL-1 production in the dorsal horn. Immunofluorescence revealed increased microglial IL-1 production in L4/L5 dorsal horn microglia cells only in the tCRPS group (Fig.6A), while IL-1was not detected. We then examined whether the tCRPS phenotype would be altered by genetic knockout (KO) of IL-1. We found that CRPS IgG-injected IL-1αβ KO mice failed to develop enhanced hyperalgesia and showed even less post-traumatic paw swelling (Fig.6 B-C) than mice treated with healthy IgG. To investigate whether increased microglial IL-1β production is sufficient to mediate the effects of CRPS IgG on increased mechanical hyperalgesia, we generated a novel IL-1β floxed(fl/fl) mouse line. Exon 4-5 of the IL-1B gene was flanked with loxP sites, resulting in the generation of IL-1βfl/fl allele (SI appendix Fig.S11). IL-1βfl/fl mice were crossed with Cx3cr1CreER mice  ADDIN EN.CITE (20) resulting in microglial deletion of IL-1β upon tamoxifen administration (M-IL-1 KO), while most peripheral Cx3cr1-positive cells recovered IL-1β production due to their higher turnover as shown by using other cre-dependent reporter lines previously  ADDIN EN.CITE (20). In fact, IL-1β protein levels were markedly reduced in IL-1β KO microglia after repeated intraperitoneal injections of bacterial lipopolysacharide (LPS) compared to WT microglia, but no changes were seen in splenic macrophages derived from tamoxifen-treated Cx3cr1CreER x IL-1βfl/fl mice compared to controls (SI appendix Fig. S12). Elimination of microglial IL-1β significantly reduced mechanical hyperalgesia and paw edema in mice treated with CRPS IgG, although this effect was smaller than in the case of IL-1αβ KO mice (Fig. 6B-C). Total numbers of microglia were reduced in IL-1αβ KO mice but were not altered in response to microglial IL-1β deletion in the CRPS group (Fig.6D), suggesting that while microglial IL-1β is an important driver of chronic neuroinflammation contributing to persistent pain, other IL-1β-producing cells or actions mediated by IL-1α could also contribute to CRPS symptoms in mice. 

DISCUSSION 

Here we show in a novel enhanced passive transfer-trauma model that daily administration of IgG from patients with persistent CRPS to mice elicits intense, unilateral static mechanical hyperalgesia after hindpaw injury, which remains stable through the experimental period. This is associated with increased paw edema that resolves over time. Collectively, these features resemble the course and pathophysiology of the clinical disease (1). In these extensive integrative studies, a uniform pattern of transferred static mechanical hyperalgesia was seen with all patient preparations, highlighting that sero-negativity is unlikely to be common in patients with severe, persistent CRPS. The results emphasise the translational validity of the model and the importance of autoimmune mechanisms underpinning the pathophysiology of both clinical CRPS and experimental transferred ‘tCRPS’. 

We found that the normal, post-traumatic inflammatory response in the incised paws rapidly declined, and fully settled by day 6-13 post incision; the paw inflammation did not correlate with the degree of CRPS IgG-induced paw hyperalgesia. We found little evidence for any CRPS IgG-related enhanced paw inflammation. Our results thus demonstrate that static mechanical hyperalgesia may not depend on persistent inflammatory mediator release, highlighting that transferred CRPS (tCRPS) is not a model of enhanced post-traumatic inflammatory pain. There was however some evidence for abnormal production of two specific mediators in the CRPS group: substance P production was increased at early time points, in line with some clinical observations  ADDIN EN.CITE (21) and our earlier results  ADDIN EN.CITE (11), and there was also a mild, but significant bilateral increase in MCP-1 on day 13, the role of which will require further investigations. Although we measured common mediators of inflammation in the injured paws, and these were normal, the involvement of additional mediators cannot be excluded. 

In mice, the development of tCRPS remained restricted to the injured paw, consistent with the clinical situation, where about 90% of the cases show symptoms in only one, traumatised limb  ADDIN EN.CITE (22). The precise mechanisms through which circulating pathogenic IgG antibodies mediate both the regionally-restricted post-traumatic clinical CRPS and tCRPS are presently unclear. Early, transient trauma-induced inflammatory changes or regional opening of blood-nerve and blood- brain barriers may play a role by promoting the expression of neoantigens, or by providing IgG access to privileged sites  ADDIN EN.CITE (23). The presence of such facilitating mechanisms is supported by our in vivo imaging results which showed plasma leakage and increased myeloperoxidase (MPO) activity in the injured paw. 
Interestingly, MPO activity was variably enhanced in the animal groups injected with different CRPS IgG preparations, and there was no correlation with mechanical hyperalgesia or swelling in these same animals. These findings may resemble the strong heterogeneity seen between patients in the extent of their limb swellings, colour changes, or temperature changes, and may also reflect the observation that these clinical parameters do not necessarily correlate with the patients’ perceived pain intensities, or recorded skin sensitivities (2).

Since inflammatory changes in the paw did not appear to explain the increased mechanical hyperalgesia in the tCRPS mice, we investigated the potential role of glial responses in pain-related neuronal circuits, which have been suggested to contribute to chronification processes in post-traumatic pain models  ADDIN EN.CITE (15, 24, 25). We found that tCRPS was associated with strong microglia and astrocyte activation at all three tested levels of the nociceptive pathway, the ipsilateral spinal cord dorsal horn, the periaqueductal grey and the contralateral somatosensory cortex. In the dorsal horn, the increases in glial responses in the tCRPS vs control groups were sometimes several-fold larger than the extent of glia activation caused by the paw incision (Fig. 4), suggesting a powerful central effect of the transferred IgG.

These results raise the question how the observed profound central glial cell activation is mediated. Possible mechanisms may include i) modification of nociceptor function following direct antibody binding in the periphery as an ‘autoimmune channelopathy’ ADDIN EN.CITE (26), ii) release of yet undetermined peripheral mediators  ADDIN EN.CITE (27), iii) direct binding in the dorsal horn after temporary post traumatic opening of the blood spinal cord barrier  ADDIN EN.CITE (28), or iv) a yet missing link. Independent of the nature of these upstream mechanisms, glial activation is likely to result in the release of mediators such as IL-1, TNF-, or BDNF with consequent modification of central pain processing.  ADDIN EN.CITE (15, 29)

We hypothesized that perioperative anti-inflammatory interventions might be effective, and we initially thought that such interventions might act though the blockade of perioperative regional facilitatory factors required to render circulating CRPS autoantibodies pathogenic (4). To investigate whether such interventions could prevent the disease phenotype, we treated mice peri-traumatically with high-dose prednisolone. Prednisolone treatment temporarily interrupted the process of autoantibody-dependent sensitisation, but it did not stop it. Systemic glucocorticoids are considered potentially effective in very early CRPS, based on the results of one preliminary trial (9). The present data suggest that where patients produce harmful autoantibodies, the peri-traumatic application of glucocorticoids is unlikely to stop disease progression. In contrast, perioperative treatment with the IL-1 receptor antagonist anakinra in this CRPS model consistently prevented the tCRPS phenotype. Notably, we found that there were only minor differences in the regional paw inflammatory environment based on the production of cytokines and chemokines after treatment with (ineffective) prednisolone and (effective) anakinra (Supplementary Fig. S10); furthermore, even delayed blockade of IL-1 actions with anakinra starting on day 8 after the incision-trauma, when trauma-induced peripheral inflammatory responses had largely resolved, was highly effective, suggesting that the pertinent biological effect of anakinra treatment was not restricted to the injured paw. 

IL-1 is a potent activator of astrocytes through actions via IL-1R1, whereas both activated microglia and astrocytes can contribute to painful central sensitisation though secreting IL-1  ADDIN EN.CITE (29, 30). These actions can be effectively blocked by anakinra  ADDIN EN.CITE (31-34). In our model, augmented dorsal horn glia cell activation in the tCRPS group was fully reversed by anakinra. Since IL-1-mediated actions are involved in the cross-talk between neurons, microglia and astrocytes in promoting neuroinflammation  ADDIN EN.CITE (35, 36), we assessed glial IL-1β and IL-1α production in the spinal cord and found that microglial IL-1β production was increased on day 7 in the CRPS IgG treated group. In agreement with these data, we found that IL-1αβ KO mice were fully protected from developing the tCRPS phenotype, and associated glial activation. To specifically assess the functional role of microglial IL-1β in tCRPS-associated hyperalgesia and swelling, we generated a novel mouse strain (IL-1βfl/fl mice) enabling the deletion of IL-1β from microglia. Consistent with earlier data showing prolonged cre-dependent transgene expression in long-lived microglia, but not in peripheral macrophage populations with short turnover  ADDIN EN.CITE (20), tamoxifen treatment of Cx3cr1CreER x IL-1βfl/fl mice resulted in a marked reduction of microglial-, but not splenic, IL-1β production. As seen in IL-1αβ KO mice, the absence of microglial IL-1β production fully protected from tCRPS-associated mechanical hyperalgesia up to day 3, whereas it had a weaker effect thereafter. This highlights the importance of microglial IL-1β in the tCRPS disease process, but also the likely involvement of other cells and/or IL-1α  ADDIN EN.CITE (35). 

Strengths of our study include the robust, multi-dimensional evaluation of a novel, enhanced CRPS disease transfer model with preparations from patients whose clinical presentations differed, using outcomes designed to provide translational validity. Further strength are the comprehensive assessment of both peripheral, and central markers of immune activation and of several anti-inflammatory treatments, as well as gene knockout strategies, which has allowed a first informed suggestion for clinical studies with a licenced drug not previously reported in this patient group.

Limitations include the upper transfer limit cut-off at 13 days, which was necessary to avoid the adverse effects of serum sickness (37). However, it may be argued that the ‘chronic phase’ in this disease model starts from the second week after incision, when peripheral inflammation and symptoms in the control group resolve. As often observed with IgG disease transfer in other disease models, tCRPS does not fully match the symptoms of clinical CRPS  ADDIN EN.CITE (38). For example, overt motor dysfunction was not detected, and commonly encountered central features such as body perception abnormalities were not revealed. In line with most behavioural studies in animal models of chronic pain (39), we did not demonstrate the presence of spontaneous pain but ascertained nociceptor hypersensitivity by assessing stimulus-evoked pain (mechanical hypersensitivity). Independently, we only transferred serum IgG that was derived from patients suffering from persistent (7) Budapest CRPS, with high pain intensities (NRS >7), however these are also the patients which present the most difficult situation in the clinical practice. We cannot rule out the possibility that some patients in this group don’t have these antibodies. Since each of the seven individually tested serum IgG preparations induced the abnormal phenotype (SI appendix S1), the likelihood that we have missed the absence of such antibodies in more than half of patients of a similar population appears very low (< 1%, Methods ‘patients’ section); the development of serum diagnostic tests will be required to further detail the proportion of sero-negative patients. We did not measure epidermal nerve fibre density or length in the mouse paw skin, therefore our studies may not fully rule out mild small fibre neuropathy.   

In summary, we have devised a robust translational model reproducing pertinent aspects of an ‘idiopathic’, post-traumatic chronic pain condition. The consistent pathogenicity of various serum-IgG preparations indicates that amongst patients who have severe forms of this condition, autoantibody contribution is ubiquitous. Since abnormal signs were entirely confined to the injured side, we also established a general principle suggesting that pathogenic circulating autoantibodies can cause regionally-restricted disease when triggered by local trauma.
Our results support previous clinical observations that patients with persistent CRPS should respond to immune treatments with a reduction of at least some of their disease features  ADDIN EN.CITE (12). The clinical use of IL-1 receptor antagonists in CRPS has a broad therapeutic potential. Anakinra is clinically licensed both in the US and Europe, and short-term use has an acceptable side effect profile  ADDIN EN.CITE (40, 41). Since CRPS regularly develops in the context of elective operations, such as arthroscopy or bunion surgery, prevention of such cases would have very important implications for both patients and procedure-related healthcare, as well as societal costs (42). As our results also suggest that treatment initiated after injury resolution reverts the established transferred phenotype, clinical treatment of patients with persistent CRPS could now be tested in a trial setting. 

The cellular and molecular targets of the patient autoantibodies need to be clarified; recent results in other conditions that are not associated with trauma  ADDIN EN.CITE (26, 27) have indicated that pain sensitising autoantibodies may directly bind to sensory neurons, or indirectly to juxtapositioned cells which then release nerve-sensitising mediators. The duration of beneficial effects after the drug is withdrawn should be investigated in the present experimental model. In addition, identifying the exact cellular targets for IL-1 actions in the pathophysiology of tCRPS could facilitate the development of alternative IL-1 targeting approaches in the prevention or treatment of the clinical disease. The results of this study highlight the important role that autoantibodies can play in causing detrimental symptoms, absent tissue destruction and systemic inflammation.


MATERIALS AND METHODS

Patients, healthy controls, and serum preparation
Serum or plasma samples were obtained i) via a dedicated study designed to repeatedly acquire large volumes, ii) from waste plasma following patients’ plasma exchange treatment, iii) from patients participating in a clinical trial who never had plasma exchange (43) – the latter samples were pooled to minimise animal use. Details are provided in the SI appendix. The patients’ baseline characteristics are provided in Table 1. We calculated the probability that we missed an event rate of >50% of patients having no pain-sensitising autoantibodies by (0.5 ^ (number of experiments x fraction of positive experiments)): 0.5 ^ 7= 0.008125, i.e. <1%. IgG was prepared from plasma or serum of patients as previously described, using Protein G columns for affinity purification, followed by elution, buffering, dialysis in normal saline, and concentration to about 8 mg/ml immunoglobulin G for injection (pooled preparations 12 mg/ml)  ADDIN EN.CITE (11).

Animals
Since CRPS affects women 2-3 times more frequent than men, experiments were carried out on female mice on C57Bl/6 background (10-12 weeks-old, 18-22 g). Breeding and maintenance, and ethical procedures were as previously described  ADDIN EN.CITE (11), details in the SI appendix. 

Experimental design
After acclimatization and conditioning, three control measurements of nociception and paw volume were performed on days -4, -3, and -2. ‘Day 0’ was the starting day of intraperitoneal injections (SI appendix Fig.S13). Mice (5–7 per group) were treated daily to compensate for rapid metabolism of human IgG in the mouse (SI appendix, Methods), with 1 ml of IgG fractions (8 mg/ml) obtained from CRPS patients or healthy volunteers, or saline. 
Six hours after the injection on day 0, a standardized incision trauma was applied to the right hind-paw, as described below. All mice removed their stitches within 16 hours post-surgery. Measurements (see further below) were performed repeatedly, starting on day 1, until the respective termination day. 
Animals were sacrificed at various time-points and tissues harvested as previously described  ADDIN EN.CITE (11). In some experiments animals were perfused transcardially with PBS followed by 4% paraformaldehyde, as previously described and the whole brains and spinal cords were excised and prepared for further immunohistochemistry analyses.

Plantar skin and muscle incision
To model a CRPS-triggering injury, we used the hindpaw plantar skin- muscle incision method under general anesthesia as described earlier  ADDIN EN.CITE (11, 44) and detailed in the SI appendix. This model evokes a significant decline of the mechanonociceptive threshold, with a maximum one day after surgery, which persists for 7–8 days; the model’s early threshold normalisation was considered advantageous, minimizing any animal suffering and allowing for early assessment of IgG-induced changes. All measurements were carried out by two investigators (VT and NS), who were blinded to treatment-assignment. Blinding was performed by the technician who performed all injections but who was otherwise not involved in the study; they differentially coded the animal cages and provided the decoding-key after completion of the last measurements.

Determination of the mechanosensitivity of the paw
Most patients with CRPS have, in addition to their spontaneous pain, also pain with the application of pressure to the CRPS-affected limb (‘mechanical hyperalgesia’)  ADDIN EN.CITE (45, 46), and all patients included into this study experienced this feature. The corresponding mechano-nociceptive threshold of the plantar surface of the mouse hindpaw was determined with a dynamic plantar aesthesiometer (Ugo Basile 37400, Comerio, Italy) - a modified electronic von Frey technique - as previously described. ADDIN EN.CITE (11)  The blunt-end needle exerting an increasing force to the mouse paw provides a mild, but basically painful stimulus activating A and C fibres  ADDIN EN.CITE (47). Threshold decreases are considered as mechanical hyperalgesia and are expressed as percentage decrease of the mechano-nociceptive thresholds compared to the baseline values  ADDIN EN.CITE (48, 49).

Paw volume measurement
Limb swelling is a common feature of CRPS-affected limbs, and all included patients reported intermittent limb swelling. Mouse-paw volume was measured using plethysmometry (Ugile Basile Plethysmometer 7140, Comerio, Italy). Edema was expressed as a percentage increase compared to the baseline paw volume  ADDIN EN.CITE (48).

In vivo optical imaging of plasma leakage and neutrophil myeloperoxidase (MPO) activity 
The mechanisms underpinning CRPS IgG-enhanced paw swelling are unknown, but one possibility is augmented plasma extravasation. Intravenously injected indocyanine green (ICG), a fluorescent cyanine dye, binds to plasma proteins and remains in the healthy vasculature. Under inflammatory conditions it can be used to evaluate capillary leakage. ICG (0.5 mg/ kg) was dissolved freshly in 5% w/v aqueous solution of Kolliphor HS 15 and a macrogol-based surfactant (68), and injected intravenously (retrobulbar sinus) under ketamine (100 mg/kg; Calypsol, Gedeon Richter Plc., Budapest, Hungary) and xylazine (10 mg/kg; Sedaxylan, Eurovet Animal Health B.V., Bladel, Netherlands) anesthesia two days after the paw incision. Fluorescence imaging was performed 20 min post-injection, using a IVIS Lumina II in vivo optical imaging system (PerkinElmer, Waltham, MA, USA; auto acquisition time, f/stop = 1, binning = 2, excitation: 745 nm, emission filter: >800 nm)  ADDIN EN.CITE (50).
A luminol analogue chemiluminescent probe, L-012 (8-amino-5-chloro-7-phenylpyrido[3, 4-d]pyridazine-1,4(2H,3H) dione; Wako Pure Chemical Industries Ltd, Japan) was used for in vivo visualisation of reactive oxygen and nitrogen species (ROS/RNS) produced by MPO in neutrophils and macrophages; L-012 has a high sensitivity towards ROS/RNS  ADDIN EN.CITE (51). Mouse preparation, injection, imaging and analysis procedures were conducted as previously described and highlighted in the SI appendix  ADDIN EN.CITE (52).

Measurement of inflammatory mediators
Pro-inflammatory neuropeptides, peripherally released from sensory nerves and inflammatory cytokines released by peri-neuronal cells are abnormal in some patients with CRPS, and we measured their concentrations in the model.
The preserved frozen paws (see above) were thawed, chopped, and then homogenized in Triton X-100 and Calbiochem Protease Inhibitor Coctail containing Tris-HCl homogenisation buffer at 0 °C. Further processing details are provided in the SI appendix. We measured CGRP- and SP-like immunoreactivities in the paws by a sensitive radioimmunoassay techniques developed in our lab as previously described  ADDIN EN.CITE (11, 53, 54).
Concentrations of IL-1α, IL-1β, IL-6, TNF-α, KC (CXCL1), MCP-1, G-CSF, RANTES (CCL5), IFN-γ, IL-4 and IL-10 in mouse plasma and the paw homogenates were measured by cytometric bead array (CBA, BD Biosciences, Franklin Lakes, New Jersey, USA) as previously described  ADDIN EN.CITE (34, 55), TGF- and NGF by sandwich ELISA according to the manufacturers’ instructions (56). 

Paw skin light and electron microscopy
Following biopsy, samples were immersed into a fixative containing 2.5% glutaraldehyde buffered with phosphate buffer (PB, 0.1M, pH 7.4) for overnight at 4oC, fixed in 1% osmium tetroxide for 35 min and dehydrated with increasing concentration of ethanol. After complete dehydration, they were transferred to propylene oxide before being placed into aluminum-foil boats and then embedded into gelatin capsule containing Durcupan resin (Sigma, Budapest, Hungary). 
Semithin and ultrathin sections were cut with Leica ultramicrotom. Semithin sections were mounted on glass slides, stained with toluidine blue and examined under light microscope. Ultrathin sections were mounted on collodion-coated (Parlodion, Electron Microscopy Sciences, Fort Washington, PA) single-slot copper grids, contrasted with uranyl-acetate and lead-citrate, and were examined in JEOL 1200EX-II electron microscope. Small nerve fibre quantification methods are detailed in the Methods section oft he SI appendix.

Immunohistochemistry
Brains and L4-L6 segments of the spinal cord were removed and post-fixed for 4 h in 4%  paraformaldehyde before being placed into 30% sucrose (Duchefa Biochemie, Netherlands) in 0.1 M PBS overnight at 4°C. Sections (30 µm) were prepared using a freezing microtome (Leica Biosystems Nussloch GmbH, Germany) as free-floating sections  ADDIN EN.CITE (57, 58), and stained and mounted as described in the SI appendix. The sections (n=3-4 animal/ group) were examined by Neurolucida software (v07, MBF Bioscience, USA) using Nikon Eclipse Ni-E bright field microscope with a computer-controlled stage. A modified unbiased stereology protocol was used for quantification of GFAP or Iba1 immunoreactive cells along the nociceptive pathway, as previously described. ADDIN EN.CITE (50)
 
Immunofluorescence
Immunofluorescence to detect microglial P2Y12  ADDIN EN.CITE (59) and the production of IL-1α and IL-1β was performed on free-floating brain sections. Images were captured with a Nikon Ni-E C2+ confocal microscope (Nikon, Tokyo, Japan). 

Anti-inflammatory interventions
We investigated whether early immune suppression would alter the disease course in the model. We administered the synthetic glucocorticoid prednisolone (4 mg/kg, i.p.  ADDIN EN.CITE (60, 61), or the IL-1 receptor antagonist anakinra (10 mg/kg, i.p, Swedish Orphan Biovitrum AB (publ), SE-112 76 Stockholm). This prednisolone dose corresponds to the highest dose range used in humans (pulse therapy (62)), and  the anakinra dose is known to be pharmacologically active in mice and und is comparable to human therapeutic dosages  ADDIN EN.CITE (63-65). Control animals received respective vehicles. The first drug injection was 3 h prior to the plantar skin and muscle incision, and at least 4 h after IgG or control treatment. Drug treatment was then repeated daily through the experimental period. Delayed anakinra treatment was administered daily between days 8-13.

Generation of IL-1 β floxed mice and microglial IL-1β KO mice
Il1btm1a(EUCOMM)Hmgu embryonic stem cells (66) were purchased from the European Mouse Mutant Cell Repository (EuMMCR). Cells from clone HEPD0840-8-E03 were prepared for microinjection according to previously published protocol  ADDIN EN.CITE (67) with minor modifications (see supplementary methods) then microinjected into 4 to 8 cell B6N-Tyrc-Brd/BrdCrCrl embryos. Surviving embryos were surgically implanted into the oviduct of day 0.5 post-coitum pseudopregnant mice. Resulting black/white C57BL/6N chimeras were back-crossed onto C57BL/6N wild-type mice to assess germline penetrance. Potential founder mice were screened by PCR for LacZ, Neo and LoxP sites. This line was further crossed with C57BL/6N-Tg(CAG-Flpo)1Afst/Mmucd mice. The flp recombinase expression provided by this line resulted in a "conditional ready" (floxed) Il1btm1c(EUCOMM)Hmgu allele where exons 4 and 5 are flanked by loxP sites. To generate microglial IL-1β KO mice, IL-1β floxed mice were crossed with tamoxifen-inducible B6.129P2(C)-CX3CR1tm2.1(cre/ERT2)Jung/J mice (JAX stock #020940). ADDIN EN.CITE (20)

Statistical analysis
Data shown are means ± SEM, and two-way repeated measures ANOVA followed by Bonferroni’s post hoc test was used for comparison of threshold values between groups at respective timepoints. One-way ANOVA followed by Bonferroni's post hoc test was used for analysis of the immunochemistry and cytokine results. A value of p < 0.05 was considered statistically significant.
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Figure Legends

Fig. 1. Effect of intraperitoneal injection of serum IgG derived from complex regional pain syndrome (CRPS) patients or healthy controls on plantar incision-induced mechanical hyperalgesia (A) and swelling (B) of the injured mouse hindpaw. IgG was administered daily, starting on day 0. The right hindpaws were incised on day 0, about 6 h after immunoglobulin injection. Shown are pooled results from all three long-term experiments to either day 10 or day 13, with three different IgG preparations (#2, 3, 4) (see patients details in supplementary Table S1, individual results in Figure 2). Data are means + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 (vs. saline-treated control mice), #p < 0.05, ###p < 0.001 (vs. healthy IgG-treated mice); two-way ANOVA followed by Bonferroni’s multiple comparison test. ‘Healthy’=healthy control IgG injected group; ‘CRPS’=CRPS IgG injected group. 

Fig. 2. Imaging reactive oxygen species demonstrates the development of inflammation in the injured hindpaws of mice. In vivo images of L-012 - derived bioluminescence were obtained during general anaesthesia on days 2, 6 and 13 after paw incision. Typical images, with red colour indicating strong bioluminescence, are shown in (A), and quantification of the bioluminescence-intensity in (B). Data at each time point represent the pooled results from experiments conducted with separate CRPS/healthy control IgG preparations (number of preparations per time point in brackets, details in the SI appendix Figure S4 and Table S2), and are shown as means  SEM of n= 6-18 mice/group, *p < 0.05, **p < 0.01, ***p < 0.001 vs. respective control groups, #p < 0.05, ##p < 0.01 vs. respective intact side; one-way ANOVA followed by Bonferroni’s multiple comparison test. ‘Healthy’=healthy control IgG injected group; ‘CRPS’=CRPS IgG injected group. 

Fig. 3. Effects of human IgG transfer on sensory neuropeptide and inflammatory cytokine concentrations in the hindpaws. Concentrations of (A) SP and (B) CGRP were measured by radioimmunoassay in hindpaw homogenates excised after sacrifice. Concentrations of (C) IL-6, (D) TNF-α, (E) MCP-1 and (F) IL-1β were measured by cytometric bead array from the same samples. Data are from 1-3 experiments per time point (bracket below x-axis) each with different patient preparations. Shown are means ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 respective control groups, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. respective intact side; one-way ANOVA followed by Bonferroni’s multiple comparison test. ‘Healthy=healthy control IgG injected group; ‘CRPS’=CRPS IgG injected group.

Fig. 4. Glial activation in the L5 spinal cord dorsal horn, ipsilateral to the paw injury. Panels (A-C) show GFAP immunopositivity marking astrocytes, and panels (G-I) show Iba1 immunopositivity marking microglia cells, with (A, G) saline, (B, H) healthy control IgG, and (C, I) CRPS IgG injections. The GFAP immunopositive sections shown are from day 6-, and Iba1 sections from day 13 after paw incision. Quantification of astrocyte reactivity (D-F) and microglia staining (J-L) in lamina I-II dorsal horn of the L4-L6 spinal cord, and deeper laminae, at 3, 6, and 13 days post hindpaw incision. Each panel represents the pooled results from 2 experiments with 2 different samples (#3, #4). Shown are means ± SEM of 6-7 mice per group, *p< 0.05, **p< 0.01, ***p< 0.001 vs. respective control groups, #p< 0.05, ##p< 0.01, ###p< 0.001 vs. respective contralateral side; one-way ANOVA followed by Bonferroni’s modified post hoc test. ‘Healthy’=healthy control IgG injected group; ‘CRPS’=CRPS IgG injected group.

Fig. 5. Effects of prophylactic steroid or anakinra treatment (days 0-6), and delayed (therapeutic) anakinra treatment on CRPS IgG induced mechanical hyperalgesia, and glial activation in the spinal cord. Panels (A, B) show mechanical hyperalgesia in groups of animals injected intraperitoneally first with human IgG or saline, and 3 hours later with 4 mg/kg of prednisolone or 10 mg/kg anakinra, or saline vehicle, on each day between days 0-6. Panels (D, E) show dorsal horn glia cell activation in these mice on day 6, (D): GFAP (astrocyte); (E): Iba-1 (microglia). Results represent the average values derived from two independent experiments with different preparations for each treatment, four experiments in total; saline, healthy control IgG, and CRPS IgG outcomes are pooled from these experiments. (C, F) - late anakinra treatment starting day 8, (C) - behavioural outcome, (F) - dorsal horn microglia cell count on day 13. Data are shown as means + SEM. Significance symbols for the behavioural data: *p < 0.05, **p < 0.01, ***p < 0.001 (CRPS IgG vs. saline-treated control mice), #p < 0.05, ###p < 0.001 (CRPS IgG vs. healthy control IgG-treated mice), +++p < 0.001 (anakinra + CRPS IgG vs. CRPS IgG injected mice); two-way ANOVA followed by Bonferroni’s multiple comparison test. Significance immunohistochemistry data: *p< 0.05, **p< 0.01, ***p< 0.001 vs. respective control groups, #p< 0.05, ##p< 0.01, ###p< 0.001 vs. respective contralateral side; one-way ANOVA followed by Bonferroni’s modified post hoc test. ‘Healthy’=healthy control IgG injected group; ‘CRPS’=CRPS IgG injected group. 

Fig. 6. Deletion of IL-1αβ or microglia-derived IL-1β fully or partially prevents development of the CRPS IgG induced phenotype in mice. (A): A population of microglia identified by immunostaining against P2Y12, a specific microglial marker in the brain  ADDIN EN.CITE (59) display a morphologically activated phenotype and show immunopositivity for IL-1β at day 7 in the deep laminae of the L4-L5 spinal cord near the central canal; scale bar: 50μm. (B, C) IL-1αβ KO mice are fully-, and M-IL-1βKO are partially protected from the development of the CRPS IgG induced phenotype; (B) paw hyperalgesia, (C) paw edema. (D) CRPS IgG induced microglia activation is abrogated in IL-1αβ KO, but not in M-IL-1β KO mice. Data are pooled from two experiments with different CRPS IgG preparations for each mouse type and are shown as means + SEM. Significance in (B, C): *p < 0.05, **p < 0.01, ***p < 0.001 (CRPS IgG WT vs. healthy IgG WT), #p < 0.05, ###p < 0.001 (CRPS IgG M-IL-1β KO/ CRPS IgG IL-1αβ KO vs CRPS IgG WT), +p < 0.05, ++p < 0.01, +++p < 0.001 (CRPS IgG IL-1αβ KO vs. CRPS IgG M-IL-1β KO); two-way ANOVA followed by Bonferroni’s multiple comparison test. Significance values in (D): *p< 0.05, **p< 0.01, ***p< 0.001 vs. respective control groups, #p< 0.05, ##p< 0.01, ###p< 0.001 vs. respective contralateral side; one-way ANOVA followed by Bonferroni’s modified post hoc test. ‘Healthy’=healthy IgG injected group; ‘CRPS’=CRPS IgG injected group. 
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